Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Middle Meningeal Artery Embolisation in Chronic Subdural Hematoma

NCT: NCT07751887 · ACTIVE_NOT_RECRUITING

NCT IDNCT07751887
StatusACTIVE_NOT_RECRUITING
Start Date2026-06-01
Completion2029-06-01
SponsorUniversity Hospital Hradec Kralove (OTHER)
First posted
Last updated

Brief Summary

This international multicenter study evaluates the efficacy and safety of middle meningeal artery embolization (MMAE) using PVA particles or liquid embolic agents as a perioperative treatment to prevent the recurrence of chronic subdural hematoma (cSDH). All participating patients across centers in the Czech Republic and Slovakia will receive the minimally invasive MMAE procedure within 7 days prior to or after surgical evacuation, with the primary goal of assessing hematoma recurrence rates and procedure-related complications over a 90-day follow-up period.

Frequently Asked Questions

What is Middle Meningeal Artery Embolisation in Chronic Subdural Hematoma?

Middle Meningeal Artery Embolisation in Chronic Subdural Hematoma is a clinical trial registered under NCT07751887. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT07751887?

The current status of NCT07751887 (Middle Meningeal Artery Embolisation in Chronic Subdural Hematoma) is: ACTIVE_NOT_RECRUITING.

When did Middle Meningeal Artery Embolisation in Chronic Subdural Hematoma start?

Middle Meningeal Artery Embolisation in Chronic Subdural Hematoma started on 2026-06-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.